GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin

Metabolic control in type 1 diabetes (T1D) remains challenging. Despite advances in insulin therapies and technology,1 most individuals fail to achieve glycaemic targets and remain at risk of hypoglycaemia, high glucose variability, ketoacidosis, weight gain, oxidative stress, and cardiovascular/renal complications. Disrupted intra-islet insulin regulation of glucagon secretion also leads to hyperglucagonaemia.2